MRE-269 structure
|
Common Name | MRE-269 | ||
---|---|---|---|---|
CAS Number | 475085-57-5 | Molecular Weight | 419.516 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 602.1±55.0 °C at 760 mmHg | |
Molecular Formula | C25H29N3O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 318.0±31.5 °C |
Use of MRE-269MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. |
Name | {4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic acid |
---|---|
Synonym | More Synonyms |
Description | MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. |
---|---|
Related Catalog | |
Target |
IP Receptor |
In Vitro | MRE-269 induces endothelium-independent vasodilation of rat extralobar pulmonary artery (EPA). MRE-269 or other IP receptor agonists including epoprostenol, iloprost, treprostinil and beraprost increase cAMP levels in hPASMC[1]. MRE-269 induces concentration-dependent vasodilation in LPA(+), LPA(-), and SPA(-)[3]. |
In Vivo | The vasorelaxant effects of MRE-269 on rat small intralobar pulmonary artery (SIPA) and EPA are the same, while the other IP receptor agonists induce less vasodilation in SIPA than in EPA[1]. MRE-269 produces substantial relaxation of rat small pulmonary artery, although its effects are only significant at high concentrations of above 10 μM (pEC50, 4.98±0.22). By contrast, in rat small pulmonary veins, MRE-269 only produces minimal relaxation over the whole concentration range, with only significant relaxation occurring at the two highest doses of MRE-269 of 10 and 100 μM[2]. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 602.1±55.0 °C at 760 mmHg |
Molecular Formula | C25H29N3O3 |
Molecular Weight | 419.516 |
Flash Point | 318.0±31.5 °C |
Exact Mass | 419.220886 |
PSA | 75.55000 |
LogP | 5.09 |
Vapour Pressure | 0.0±1.8 mmHg at 25°C |
Index of Refraction | 1.588 |
Storage condition | 2-8℃ |
Precursor 1 | |
---|---|
DownStream 0 |
Acetic acid, 2-[4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]- |
MRE-269 |
2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID |
2-(4-{[(3,5-dichlorophenyl)carbamoyl]amino}phenoxy)-2-methylpropanoic acid |
{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid |
{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid |
4-(3,5-dichlorophenylureido)phenoxyisobutyric acid |
{4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic acid |
ACT-333679 |
2-<4<<<(3,5-dichlorophenyl)amino>carbonyl>amino>phenoxy>-2-methylpropionic acid |
2-{4-[N'-(3,5-dichlorophenyl)ureido]phenoxy}isobutyric acid |
2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic acid |
Propanoic acid,2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl |